IMMUNARTES LLC

Chicago, IL · Biotech · Private

SpA* vaccine against Staphylococcus aureus, a detoxified staphylococcal protein A antigen formulated with adjuvants to elicit TH1/TH17 and humoral immune responses

immunartes.com →
Grants
$512K
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of a Vaccine for Staphylococcal Infections$257,842
Federal grantDepartment of Health and Human Services · Phase I · Optimal adjuvant/antigen formulation toward a Staphylococcus aureus human vaccine$253,925
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1643T3S Technologies, Inc.——
1644MIDI, INC.——
1645CANCER TARGETED TECHNOLOGY, LLC——
1646IMMUNARTES LLC——
1647GENERAL NUTRACEUTICAL TECHNOLOGY LLC——
1648Boston Immune Technologies And Therapeutics Inc.——
1649Respana Therapeutics, Inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.